98 related articles for article (PubMed ID: 3943469)
1. [Longitudinal growth of patients with homozygote beta-thalassemia during continuous subcutaneous infusion of deferoxamine].
Krüger N; Stubbe P; Tillmann W; Schröter W
Dtsch Med Wochenschr; 1986 Jan; 111(5):176-81. PubMed ID: 3943469
[TBL] [Abstract][Full Text] [Related]
2. [Continuous subcutaneous deferoxamine infusions in thalassemia major. Improvement in glucose tolerance].
Krüger N; Stubbe P; Tillmann W; Schröter W
Dtsch Med Wochenschr; 1986 May; 111(18):698-701. PubMed ID: 3486106
[TBL] [Abstract][Full Text] [Related]
3. [Continuous subcutaneous deferoxamine treatment in thalassemia major. Decrease of hemosiderosis and improvement of liver function].
Krüger N; Ullrich D; Tillmann W; Schröter W
Dtsch Med Wochenschr; 1985 Nov; 110(48):1848-51. PubMed ID: 4064938
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation of iron balance in homozygous beta-thalassemia subjects treated with desferrioxamine administered subcutaneously].
Ferrara M; Galdo Capotorti M; Ponte G; Esposito L
Pediatria (Napoli); 1983; 91(4):371-7. PubMed ID: 6545400
[No Abstract] [Full Text] [Related]
5. The effect of platyspondyly and pubertal growth spurt on the stature of patients with beta-thalassaemia major.
Low CK; Kwan YW; Cheung PT; Li MC; Ha SY; Lau YL; Karlberg J
Chin Med J (Engl); 1998 Aug; 111(8):731-5. PubMed ID: 11245030
[TBL] [Abstract][Full Text] [Related]
6. [Deferoxamine in hemosiderosis. Fecal iron excretion during continuous subcutaneous infusion].
Krüger N; Kijewski H; König R; Tillmann W; Schröter W
Dtsch Med Wochenschr; 1984 Nov; 109(44):1682-5. PubMed ID: 6489181
[TBL] [Abstract][Full Text] [Related]
7. [Thalassemia major: chelating therapy with deferoxamine].
Abreu de Miani MS; Sanchis de Herrlein MS; Peñalver JA
Medicina (B Aires); 1985; 45(3):231-4. PubMed ID: 3841934
[No Abstract] [Full Text] [Related]
8. Short-term therapy with recombinant growth hormone in polytransfused thalassaemia major patients with growth deficiency.
Cavallo L; Gurrado R; Zecchino C; Manolo F; De Sanctis V; Cisternino M; Caruso-Nicoletti M; Galati M
J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():845-9. PubMed ID: 10091155
[TBL] [Abstract][Full Text] [Related]
9. [Intravenous administration of deferoxamine in over-night hospitalization: efficacy and good psychological tolerance in thalassemic children].
Bachelot C; Plantaz D
Pediatrie; 1990; 45(9):619-23. PubMed ID: 2175425
[TBL] [Abstract][Full Text] [Related]
10. Maintenance treatment with desferrioxamine via subcutaneous injections in a patient with HbE thalassaemia.
van Deursen CT; Goey SH; Fickers MM
Neth J Med; 1988 Oct; 33(3-4):178-81. PubMed ID: 3226450
[No Abstract] [Full Text] [Related]
11. Growth and sexual maturation in children with thalassemia major.
Yesilipek MA; Bircan I; Oygür N; Ertug H; Yegin O; Güven AG
Haematologica; 1993; 78(1):30-3. PubMed ID: 8491419
[TBL] [Abstract][Full Text] [Related]
12. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.
Shalitin S; Carmi D; Weintrob N; Phillip M; Miskin H; Kornreich L; Zilber R; Yaniv I; Tamary H
Eur J Haematol; 2005 Feb; 74(2):93-100. PubMed ID: 15654898
[TBL] [Abstract][Full Text] [Related]
13. Stature and longitudinal growth in thalassemia major. A study of 229 Greek patients.
Constantoulakis M; Panagopoulos G; Augoustaki O
Clin Pediatr (Phila); 1975 Apr; 14(4):355-7/362-8. PubMed ID: 164311
[TBL] [Abstract][Full Text] [Related]
14. Relationships among tempo of maturation, midparent height, and growth in height of adolescent boys and girls.
Kozieł S
Am J Hum Biol; 2001; 13(1):15-22. PubMed ID: 11466962
[TBL] [Abstract][Full Text] [Related]
15. [Recommendations for therapy of juvenile thalassemia major].
Siller V; Frank M
Fortschr Med; 1980 Nov; 98(44):1720-9. PubMed ID: 7007189
[TBL] [Abstract][Full Text] [Related]
16. Growth and development in patients with homozygous beta-thalassemia in Hong Kong.
Li AM; Cheng MY; Low WD
Birth Defects Orig Artic Ser; 1987; 23(5A):441-8. PubMed ID: 3689931
[No Abstract] [Full Text] [Related]
17. [Growth and endocrine function in major thalassemia].
Pérignon F; Brauner R; Souberbielle JC; de Montalembert M; Girot R
Arch Fr Pediatr; 1993 Oct; 50(8):657-63. PubMed ID: 8002739
[TBL] [Abstract][Full Text] [Related]
18. The effects of subcutaneous deferoxamine administration on renal function in thalassemia major.
Koren G; Kochavi-Atiya Y; Bentur Y; Olivieri NF
Int J Hematol; 1991 Oct; 54(5):371-5. PubMed ID: 1756248
[TBL] [Abstract][Full Text] [Related]
19. The effect of subcutaneous deferoxamine on the cardiac profile of thalassemia major: a five-year study.
Giardina PJ; Ehlers KH; Engle MA; Grady RW; Hilgartner MW
Ann N Y Acad Sci; 1985; 445():282-92. PubMed ID: 3860132
[No Abstract] [Full Text] [Related]
20. Iron absorption in non-transfused iron loading anaemias: prediction of risk for iron loading, and response to iron chelation treatment, in beta thalassaemia intermedia and congenital sideroblastic anaemias.
Pippard MJ; Weatherall DJ
Haematologia (Budap); 1984; 17(1):17-24. PubMed ID: 6724353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
